GLP-1 statistics 2026: trial results, use and cost in numbers
GLP-1 statistics from trial papers, FDA labels, CDC and KFF: weight loss, side effects, stopping, regain, use and costs. Updated November 10, 2026.
Clinical guides, organized for real decisions
Search the latest HealthRX.com articles on GLP-1 medicine, hormone therapy, peptides, labs, costs, coverage, side effects, and dosing.
14,938clinical articles
9core categories
Nov 10, 2026latest review
Latest clinical articles
Showing 60 of 14,938 clinical reviews.
Hair loss statistics 2026: prevalence and treatment results
Hair loss figures from published trials and FDA labels: how common it is by age and sex, and what finasteride, minoxidil and JAK inhibitors did.
Peptide statistics 2026: what the human studies actually show
A plain count of the human evidence on BPC-157, ipamorelin, tesamorelin, CJC-1295, KPV and Semax, from papers, FDA documents and trial registries.
Retatrutide Insurance Coverage: Check the Right Plan Documents
Find the right insurance drug list, verify your exact plan and medicine, and record documented coverage requirements and pharmacy cost estimates.
What Drives 5-Amino-1MQ Pricing
5-amino-1MQ pricing varies by purity testing, batch source, and seller type, not by proven efficacy, since no dosing or quality standard is FDA-established.
5-Amino-1MQ 'Dosing': What Vendors Claim and Evidence Supports
No validated human dose of 5-amino-1MQ exists. Rodent studies inform mechanism, not milligrams. Here is what the evidence actually supports.
Editorial: 5-Amino-1MQ Is a Promising Mouse Drug Being Sold to Humans
5-amino-1MQ has strong rodent NNMT-inhibition data and no human trials. This editorial argues the mouse-to-human translation gap is being sold as settled science.
5-Amino-1MQ's US Regulatory Status
5-amino-1MQ has no FDA-approved use and is not on the 503A bulks list. Here is what its current regulatory status actually means for buyers.
5-Amino-1MQ and Muscle: The Regeneration Research
5-amino-1MQ is studied in preclinical models for NNMT-linked muscle metabolism; no cited human sarcopenia trial has tested the compound itself as of Sept 2026.
5-Amino-1MQ, NAD+, and Methylation: The Biochemistry
5-Amino-1MQ inhibits NNMT, an enzyme linking methylation and NAD+ salvage; the mechanism is well studied preclinically, human metabolic effects are not.
Why 5-Amino-1MQ Is Sold as a Capsule: Bioavailability Notes
5-amino-1MQ is capsule-dosed because it is a small molecule, not a peptide, but oral rat pharmacokinetic data does not establish human bioavailability or efficacy.
5-Amino-1MQ Safety: What Is Known and What Is Not
No human safety data exist for 5-amino-1MQ. Here is what animal and enzymology research suggests about risk, and what remains unverified.
5-Amino-1MQ vs Berberine for Metabolic Health
5-amino-1MQ has no human trials; berberine has human RCT history. Compare evidence tiers, mechanisms, and what each gap means for decisions.
5-Amino-1MQ vs GLP-1 Medications: No Contest, Explained
5-amino-1MQ has no human weight-loss trials; semaglutide and tirzepatide have large randomized trials and FDA approval. Here is why that gap matters.
5-Amino-1MQ for Weight Loss: Mouse Data vs Marketing
5-amino-1MQ weight loss evidence comes entirely from mouse studies. No human trials exist. Here is what the rodent data actually showed.
The 5-Amino-1MQ Market: What to Watch For
5-amino-1MQ is sold as an unregulated research chemical with no FDA-approved use. Here is how to read purity claims and vendor red flags.
How NNMT Inhibition Works: The Metabolic Logic
5-amino-1MQ blocks the NNMT enzyme in rodent studies, altering NAD+ and methylation balance in fat cells; human mechanism data remain unpublished as of 2026.
What Is 5-Amino-1MQ? The NNMT Inhibitor, Explained
5-amino-1MQ is an experimental small-molecule NNMT inhibitor, not a peptide or approved drug. Evidence is mostly preclinical.
DSIP Clinical Trials: The Complete History
Small intravenous DSIP trials from 1981 to the early 1990s gave weak insomnia results, and FDA's 2026 review proposed against compounding use.
What Drives DSIP Pricing
DSIP prices vary because it is an unapproved, non-503A compounded peptide sold in an unregulated gray market, not because of graded quality tiers.
DSIP Dosing: What Protocols Exist and What Supports Them
No validated human DSIP dosing protocol exists. One small trial and scattered anecdotal regimens are often confused with clinical guidance. Here is the difference.
Editorial: Why the FDA Committee Said No to DSIP
DSIP's advisory committee rejection traces to thin, decades-old human trials. Here is the evidence gap and what data could actually close it.
DSIP FDA Status: Withdrawn Nomination, Rejected Recommendation
DSIP has no FDA-approved use. Its bulks nomination was withdrawn and an FDA advisory committee voted against adding it in 2026.
DSIP for Sleep: What the Research Actually Shows
DSIP's name promises delta sleep, but human trial evidence is one small 1992 study. Here is what it found, and what it did not.
How DSIP Might Work: Mechanism Hypotheses
DSIP has no confirmed receptor or validated mechanism. Here is what the hypotheses actually claim, what evidence supports them, and what remains unproven.
DSIP and Pain: The Analgesia Research Thread
FDA's 2026 review of DSIP (emideltide) covered insomnia, narcolepsy and opioid withdrawal, not pain. The human studies were small and intravenous.
DSIP Reconstitution and Storage Guide
DSIP has no FDA approval and no published stability data; general peptide handling principles apply, but sterility and dosing risks remain unresolved.
DSIP Side Effects and Safety: The Documented Record
DSIP's human safety data comes from three small older trials; most research is rodent-based, and unregulated sourcing is the larger practical risk in 2026.
DSIP and the Stress Axis: Cortisol and ACTH Research
DSIP's link to cortisol and ACTH rests on old, unreplicated studies; current HPA-axis research does not include DSIP-specific trials in this evidence set.
DSIP vs Melatonin: An Honest Comparison
DSIP has thin, largely animal or non-English human data and no FDA status; melatonin is a widely used OTC supplement with a far larger published record.
DSIP vs Prescription Sleep Medications
DSIP has no FDA approval and thin trial evidence; FDA notes that approved treatments already exist for chronic insomnia.
How People Get DSIP, and the Risks at Each Route
DSIP has no FDA-approved use and no legal 503A compounding pathway. Here is how it actually reaches buyers, and the red flags at each route.
What Is DSIP? The Delta Sleep-Inducing Peptide, Explained
DSIP (emideltide) is a 1970s rabbit-brain-derived peptide with no FDA-approved use and thin, mostly small or animal-based sleep evidence.
Follistatin-344 'Dosing': Why No Real Protocol Exists
No validated human dosing for Follistatin-344 exists. Vendor protocols are unsourced extrapolations, not evidence. Here is what the data actually shows.
Follistatin-344 vs 315: The Splice Variants Explained
Follistatin-344 is named for a precursor length, not the FST315 form that actually circulates in human serum. The splice variant biology, explained plainly.
What Drives Follistatin-344 Pricing
Follistatin-344 prices vary widely because of protein synthesis cost, purity claims, and zero regulatory price anchoring, not proven potency differences.
Editorial: Follistatin-344 Is Mostly a Story We Tell Ourselves
Belgian Blue cattle photos are not human trial data. Follistatin-344 has no controlled human evidence for muscle gain, and the gap matters.
Follistatin-344's US Regulatory Status
Follistatin-344 has no FDA-approved use, is not on the 503A bulks list, and lacks human clinical trial evidence for any claimed benefit.
Follistatin Gene Therapy Trials: What Actually Happened
Follistatin trials used AAV gene therapy in Becker MD and IBM patients, not injectable peptide vials. Here is what the published data actually shows.
Follistatin and Muscle Growth: Animal Data vs Human Reality
Follistatin-344 grows muscle dramatically in mice and cell models. Human clinical trial data on follistatin-344 for muscle growth does not exist. Here is the actual evidence map.
How Follistatin Blocks Myostatin (and Activin)
Follistatin-344 blocks myostatin by structural binding, but the same domain also binds activin non-selectively, which is the real safety question.
Follistatin, Exercise, and Natural Levels
Exercise and weight loss change circulating follistatin and FSTL1 in trials, but no study measured the injectable peptide Follistatin-344 itself.
Follistatin-344 Risks: Off-Target Effects Worth Taking Seriously
Follistatin-344 blocks activin signaling, which also governs fertility, fibrosis, and bone remodeling. Human safety data for this compounded peptide are absent.
Follistatin-344 vs Creatine: An Uncomfortable Comparison
Creatine has human trials, including kidney-function trials, and a published safety position. This page cites no human outcome trial of Follistatin-344.
The Follistatin-344 Market: Quality and Authenticity Risks
Follistatin-344 is a folded protein, not a simple peptide chain, which makes counterfeit and degraded vials far harder to detect than with small peptides.
The Myostatin Inhibitor Landscape in 2026
Follistatin-344 sits outside every legitimate myostatin-inhibitor track: not FDA-approved, not on the 503A bulks list, and untested in humans.
What Is Follistatin-344? The Myostatin-Binding Protein
Follistatin-344 is a myostatin-binding splice variant studied mainly in gene-therapy models; no FDA approval or human injectable safety data exist.
How People Get Selank, and What to Watch For
Understand Selank access claims, research-vendor labels, certificates of analysis, and the difference between published studies and a US prescription pathway.
Selank for Anxiety: Reading the Actual Evidence
Selank's anxiolytic evidence comes from Russian human trials and animal models, not FDA-reviewed trials. Here is what the studies actually show.
What Drives Selank Pricing
Selank cost varies by purity testing, peptide length, batch size, and vendor compliance rather than dosing form. No FDA-approved product exists to anchor pricing.
Selank Dosing: Nasal Spray vs Injection
Selank has no approved or validated dose. This compares reported intranasal and injected regimens from research use and flags what remains unverified.
Editorial: Selank Is Interesting. The Evidence Base Has a Geography Problem
Selank's anxiolytic evidence comes almost entirely from Russian-language trials. Here is what independent replication would need to show.
Selank's US Regulatory Status, Plainly
Selank has no FDA approval, is not FDA-cleared as a drug, and is not on the 503A bulk substances list as of September 2026. Here is what that actually means.
Selank's Immune and Interferon Research
Selank is described as a tuftsin analog. The only human immune data cited is a 2008 Russian cytokine study, and no cited abstract reports interferon.
Selank's Mechanism: Tuftsin, GABA, and BDNF Threads
Selank's proposed mechanisms rest on binding assays and small human biomarker and imaging studies; none confirms how it works in the brain.
Selank's Nootropic Claims vs the Evidence
Selank is marketed as a nootropic for memory and focus, but no human cognition trials exist. This audit checks each claim against the actual literature.
Selank Nasal Spray: What Stability and Storage Claims Need to Show
Evaluate Selank nasal-spray shelf-life claims, formulation differences, certificates of analysis, and why general peptide handling does not validate a storage period.
Selank Side Effects and Safety Profile
Selank's reported tolerability in small trials looks favorable, but long-term human safety data are absent and sourcing quality is the bigger real-world risk.
Stacking Selank with Semax: Rationale and Cautions
No trials test Selank plus Semax together. Both are unapproved research peptides with limited human data individually; combining them adds untested variables.
Selank vs Benzodiazepines: The Comparison People Ask For
Selank is not a benzodiazepine and has no FDA approval. Evidence is limited to small Russian trials; dependence data comparable to benzodiazepines does not exist.
Showing the first 60 matches among the loaded articles. Use the page links below to browse the complete library.